These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 39046941

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
    Fakhri B, Emechebe N, Manzoor BS, Jawaid D, Alhasani H, Edwards M, Tuncer HH.
    JCO Oncol Pract; 2024 Aug; 20(8):1132-1139. PubMed ID: 38626366
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A, Shapouri S, Manzoor BS, Ravelo A, Sail K, Qendri V, van de Wetering G, Davids MS.
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [Abstract] [Full Text] [Related]

  • 5. Frontline treatment in CLL: the case for time-limited treatment.
    Lévy V, Delmer A, Cymbalista F.
    Hematology Am Soc Hematol Educ Program; 2021 Dec 10; 2021(1):59-67. PubMed ID: 34889444
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
    Lin VS, Lew TE, Handunnetti SM, Blombery P, Nguyen T, Westerman DA, Kuss BJ, Tam CS, Roberts AW, Seymour JF, Anderson MA.
    Blood; 2020 Jun 18; 135(25):2266-2270. PubMed ID: 32244251
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Thompson MC, Mato AR.
    Hematol Oncol Clin North Am; 2021 Aug 18; 35(4):793-806. PubMed ID: 34174986
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF, Feres CCP, Teixeira LLC, Hamerschlak N.
    Curr Treat Options Oncol; 2021 Jun 10; 22(8):66. PubMed ID: 34110507
    [Abstract] [Full Text] [Related]

  • 13. Upfront therapy: the case for continuous treatment.
    Tam CS.
    Hematology Am Soc Hematol Educ Program; 2021 Dec 10; 2021(1):55-58. PubMed ID: 34889433
    [Abstract] [Full Text] [Related]

  • 14. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
    Bennett R, Anderson MA, Seymour JF.
    J Hematol Oncol; 2023 Jul 08; 16(1):72. PubMed ID: 37422670
    [Abstract] [Full Text] [Related]

  • 15. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
    Huang Q, Emond B, Lafeuille MH, Gupta D, Lefebvre P, Sundaram M, Mato A.
    Curr Med Res Opin; 2020 Dec 08; 36(12):2009-2018. PubMed ID: 33044848
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.